Health Technology

Sumitomo Pharma Co., Ltd.

In the news

Cutting-edge drugs must be affordable, Nobel laureate tells Davos Jan 22, 2020
Japan's midsize drugmakers find niche in richer Southeast Asians Aug 25, 2019
Japan keeps edge in stem-cell medicine with heart study May 17, 2018
Advanced medical care for pets catches on fast in Japan Apr 2, 2018
China sees influx of blockbuster drugs as market grows Mar 5, 2018

See more articles on Sumitomo Pharma Co., Ltd.

Business Summary

Sumitomo Pharma Co., Ltd. engages in manufacture, sale, import, and export of pharmaceutical products. It operates through the Pharmaceutical Business and Other Business segments. The Pharmaceutical Business segment manufactures and sells generic and prescription drugs in Japan, North America, China, and other overseas countries. The Other Business segment division includes food ingredients, additives, chemical products, veterinary drugs, and diagnostic reagents. The company was founded on May 14, 1897 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2022	JPY	USD
Revenue	560,035M	4,983.72M
Gross Profit	371,177M	3,303.08M
Operating income	56,553M	503.26M
Income before tax	82,961M	738.26M
Net income	56,413M	502.01M
EBITDA	94,901M	844.52M
Diluted EPS	141.99	1.26
Dividends Per Share	28	0.24
Total Assets	1,308.00B	10,776.57M
Total liabilities	634,438M	5,227.08M
Total equity	607,888M	5,008.34M
Operating cash flow	31,239M	277.99M
	Currency in JPY	Currency in USD

Historical Data

JPY | USD

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Revenue	466,838M	459,267M	482,732M	515,952M	560,035M
Gross Profit	347,955M	337,856M	341,787M	361,600M	371,177M
Operating income	79,643M	57,207M	51,083M	68,381M	56,553M
Income before tax	84,866M	65,046M	83,947M	77,851M	82,961M
Net income	53,448M	48,627M	40,753M	56,219M	56,413M
EBITDA	92,530M	71,183M	68,448M	91,054M	94,901M
Diluted EPS	134.53	122.39	102.57	141.50	141.99
Dividends Per Share	28	28	28	28	28
Total Assets	809,684M	834,717M	1,256.53B	1,308.12B	1,308.00B
Total liabilities	356,961M	336,555M	620,674M	659,949M	634,438M
Total equity	452,723M	498,138M	532,670M	580,570M	607,888M
Operating cash flow	93,420M	48,711M	46,128M	135,601M	31,239M

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Revenue	4,212.10M	4,141.47M	4,439.90M	4,864.83M	4,983.72M
Gross Profit	3,139.46M	3,046.63M	3,143.56M	3,409.47M	3,303.08M
Operating income	718.58M	515.86M	469.83M	644.75M	503.26M
Income before tax	765.71M	586.55M	772.09M	734.04M	738.26M
Net income	482.24M	438.49M	374.82M	530.08M	502.01M
EBITDA	834.86M	641.89M	629.54M	858.53M	844.52M
Diluted EPS	1.21	1.10	0.94	1.33	1.26
Dividends Per Share	0.25	0.25	0.25	0.26	0.24
Total Assets	7,613.38M	7,541.37M	11,639.42M	11,838.25M	10,776.57M
Total liabilities	3,356.47M	3,040.65M	5,749.37M	5,972.38M	5,227.08M
Total equity	4,256.91M	4,500.50M	4,934.18M	5,254.02M	5,008.34M
Operating cash flow	842.89M	439.25M	424.26M	1,278.56M	277.99M

Valuation Measures

Mar 2022
PER	8.50
ROA	4.31%
ROE	9.49%
Operating margin	10.09%
Profit margin	10.07%

Key executives

President, Chief Executive Officer & Director: Hiroshi Nomura
Director, Head-Research & Technology: Yoshiharu Ikeda
Executive Officer & GM-Technology Research: Kenji Ueno
Executive Officer & Senior Research Director: Isao Shimizu
Managing Executive Officer: Shigeyuki Nishinaka

Shareholders

Sumitomo Chemical Co., Ltd. (51.6%)
Nomura Asset Management Co., Ltd. (3.5%)
Inabata & Co., Ltd. (3.0%)
Nippon Life Insurance Co. (1.9%)
Nikko Asset Management Co., Ltd. (1.7%)
Sumitomo Mitsui Banking Pension Fund (1.7%)
Daiwa Asset Management Co. Ltd. (1.7%)
Sumitomo Life Insurance Co. (1.4%)
The Vanguard Group, Inc. (1.0%)
Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (0.9%)

Contact Details

Website:http://www.sumitomo-pharma.co.jp
Address: 2-6-8 Dosho-machi, Chuo-Ku, Osaka, 541-0045, Japan
Phone: +81.6.6203.5321

Related Companies

Sumitomo Pharma Employee Stock Ownership Plan
Sumitomo Pharma Oncology, Inc.
Spirovant Sciences Ltd.
DS Pharma Promo Co., Ltd.
Enzyvant Therapeutics Ltd.
Sumitomo Dainippon Pharma Oncology, Inc.
Sumitovant Biophama, Inc.
Sumitovant Biopharma Ltd. (London)
Sumitovant Biopharma Ltd.
Sumitomo Pharma Pension Fund
Urovant Sciences Ltd.
Myovant Sciences Ltd.
Sumitomo Dainippon Pharma America, Inc.
Sunovion Pharmaceuticals Asia Pacific Pte Ltd.
Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.
Sumitomo Dainippon Pharma Trust
Sumitomo Pharma Food & Chemical Co., Ltd.
DS Pharma Animal Health Co., Ltd.
Sumitomo Dainippon Pharma Employee Stock Ownership Plan
Kyowa Hakko Pharmaceuticals (Suzhou) Co. Ltd.
Tanabe Seiyaku Co., Ltd. /Pet Medicine Operations/
Tolero Pharmaceuticals, Inc.
Boston Biomedical, Inc.
Sunovion Pharmaceuticals, Inc.

Competitors

Vanda Pharmaceuticals Inc.
Cerevel Therapeutics Holdings Inc
ACADIA Pharmaceuticals Inc.
Intra-Cellular Therapies, Inc.
Voyager Therapeutics, Inc.
Alkermes Plc
Innoviva, Inc.
Karuna Therapeutics, Inc.
Acorda Therapeutics, Inc.
Impel Pharmaceuticals Inc.
Gongwin Biopharm Holdings Co., Ltd.
SyneuRx International (Taiwan) Corp.
Verona Pharma plc Sponsored ADR
Bright Minds Biosciences Inc.
ATAI Life Sciences N.V.
VistaGen Therapeutics, Inc.
Supernus Pharmaceuticals, Inc.
Aerovate Therapeutics, Inc.
Aravive, Inc.
Aytu BioPharma, Inc.
BioLineRX Ltd.
Biomea Fusion Inc
Cyclacel Pharmaceuticals, Inc.
FutureChem Co., Ltd.
Geron Corporation
Gossamer Bio, Inc.
Kronos Bio Inc
Kura Oncology, Inc.
Marinus Pharmaceuticals Inc
OptiNose, Inc.

Last Updated on 26 Jan, 2023